Description
Using our intelligently designed and intuitive dataset, you can quickly understand how Biomarin Pharmaceutical Inc (BMRN) is lobbying the U.S. government, how much they’re spending on it, and most importantly – the bills and specific issues on which they lobby.
Gain an informational edge with our Lobbying Data Intelligence. Perform analysis by company, lobbyist, lobbying firm, government agency, or issue.
For lobbying firms: understand your competitors. Understand who is registering with who. Gain insight on quarterly reports and specific issues other firms are lobbying on.
Our lobbying data is collected and aggregated from the U.S. Senate Office of Public Records from 1999-present and is updated on a regular basis. We utilize advanced data science techniques to ensure accurate data points are collected and ingested, match similar entities across time, and tickerize publicly traded companies that lobby.
Our comprehensive and advanced lobbying database is completed with all the information you need, with more than 1.6 million lobbying contracts ready-for-analysis. We include detailed information on all aspects of federal lobbying, including the following fascinating attributes, among much more:
1. Clients: The publicly traded company, privately owned company, interest group, NGO, or state or local government that employs or retains a lobbyist or lobbying firm.
2. Registrants (Lobbying Firms): Either the name of the lobbying firm hired by the client, or the name of the client if the client employs in-house lobbyists.
3. Lobbyists: The names and past government work experience of the individual lobbyists working on a lobbying contract. 3. General Issues: The general issues for which clients lobby on (ex: ENV – Environment, TOB – Tobacco, FAM – Family Issues/Abortion).
4. Specific Issues: A long text description of the exact bills and specific issues for which clients lobby on.
5. Bills Lobbied On: The exact congressional bills and public/private laws lobbied on, parsed from lobbying report specific issues (ex: H.R. 2347, S. 1117, Tax Cuts and Jobs Act).
6. Agencies Lobbied: The names of one or more of 250+ government agencies lobbied on in the contract (ex: White House, FDA, DOD).
7. Foreign Entities: The names and origin countries of entities affiliated with the client (ex: BNP Paribas: France).
Gain access to our highly unique and actionable U.S. lobbying database. Further information on LobbyingData.com and our alternative datasets and database can be found on our website, or by contacting [email protected].
Frequently Asked Questions
What is Biomarin Pharmaceutical Inc (BMRN) lobbying for?
Summary of the Lobbying Data:
Biomarin Pharmaceutical Inc. hired two lobbying firms to lobby on taxation/internal revenue code, health issues, immigration, Medicare/Medicaid, and budget/appropriations. They specifically lobbied on various bills related to relief for specific individuals, Medicaid, lower costs, newborn screening, and food and drug amendments. They also lobbied on policies related to infrastructure investment, accelerated approval, rare diseases, telemental health, and drug pricing proposals, as well as issues related to the Orphan Drug Tax Credit and revising Medicaid drug rebate and third-party liability requirements. Biomarin Pharmaceutical Inc. lobbied the Senate, Department of Health & Human Services, Centers For Medicare and Medicaid Services, and House of Representatives.
Inference on Why Biomarin Pharmaceutical Inc is Lobbying on the Issues:
One could infer that Biomarin Pharmaceutical Inc is lobbying on these issues to influence policy decisions that could impact their business operations and profitability. For example, by lobbying on bills related to Medicaid and rare diseases, they could aim to secure funding or incentives for their drug development and treatment for rare diseases. They could also be advocating for changes in drug pricing proposals to benefit their customers and their business interests. Additionally, by lobbying on infrastructure investment and budget/appropriations, they could aim to secure funding or tax incentives to support research and development for their products. Overall, the company’s lobbying efforts may be aligned with their business strategy and aim to influence policies that could affect their bottom line.
